Serum osteoprotegerin is associated with vascular stiffness and the onset of new cardiovascular events in hemodialysis patients

키워드

참고문헌 (33)

1. Guerin AP, "Arterial stiffening and vascular calcifications in end-stage renal disease", Nephrol Dial Transplant, 15, pp.1014~1021 (2000)
2. Blacher J, "Arterial calficications, arterial stiffness, and cardiovascular risk in end-stage renal disease", Hypertension, 38, pp.938~942 (2001)
3. Asmar R, "Assesment of arterial distensibility by automatic pulse wave velocity measurement: validation and clinical application studies", Hypertension, 26, pp.485~490 (1995)
4. Lacey DL, "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density", Cell, 89, pp.309~319 (1997)
5. Lacey DL, "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation", Cell, 93, pp.165~176 (1998)
6. Westenfeld R, "Vascular calcification and fetuin-A deficiency in chronic kidney disease", Trends Cardiovasc Med, 7, pp.124~128 (2007)
7. Nishiura R, "Elevated osteoprotegerin levels predict cardiovascualr events in new hemodialysis patients", Am J Nephrol, 9, pp.257~263 (2009)
8. Sigrist MK, "Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification", Nephrol Dial Transplant, 24, pp.3157~3162 (2009)
9. Nakashima A, "Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients", Osteoporosis Int, 22, pp.1695~1701 (2011)
10. Speer G, "Serum osteoprotegerin level, carotid-femoral pulse wave velocity and cardiovascular survival in haemodialysis patients", Nephrol Dial Transplant, 23, pp.3256~3262 (2008)
11. Hermans MM, "Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis", Nephrol Dial Transplant, 21, pp.1293~1299 (2006)
12. Ix JH, "Fetuin-A is not associated with mortality in chronic kidney disease", Kidney Int, 72, pp.1394~1399 (2007)
13. Ketteler M, "Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a crosssectional study", Lancet, 361, pp.827~833 (2003)
14. Swedberg K, "Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology: guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology", Eur Heart J, 26, pp.1115~1140 (2005)
15. O'Rourke MF, "Clinical application of arterial stiffness: definitions and reference values", Am J Hypertens, 15, pp.426~444 (2002)
16. Park S, "The influence of serum aldosterone and the aldosterone-renin ratio on pulse wave velocity in hypertensive patients", J Hypertens, 25, pp.1279~1283 (2007)
17. Kuzniar J, "Relationship between fetuin-A concentration, elevated levels of inflammatory markers, and arterial wall stiffness in end stage kidney disease", J Ren Nutr, 18, pp.83~86 (2008)
18. Nitta K, "The progression of vascular calcification and serum osteoprogerin levels in patients on long-term hemodialysis", Am J Kidney Dis, 42, pp.303~309 (2003)
19. Barreto DV, "Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors", Kidney Int, 67, pp.1576~1582 (2005)
20. London GM, "Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency", J Am Soc Nephrol, 18, pp.613~620 (2007)
21. Lebreton JP, "Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acutephase reactant", J Clin Invest, 64, pp.1118~1129 (1979)
22. Stenvinkel P, "Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin", Kindey Int, 67, pp.2383~2392 (2005)
23. Luo G, "Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein", Nature, 386, pp.78~81 (1997)
24. Schinke T, "The serum protein alpha 2-HS glycoprotein", fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells: a possible role in mineralization and calcium homeostasis, 1996, pp.271, 20789~20796
25. Metry G, "Low serum fetuin-A concentration predicts poor outcome only in the presence of inflammation in prevalent haemodialysis patients", Eur J Clin Invest, 38, pp.804~811 (2008)
26. Honda H, "Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD", Am J Kidney Dis, 47, pp.139~148 (2006)
27. Chen HY, "Association of serum fetuin A with truncal obesity and dyslipidemia in non-diabetic hemodialysis patients", Eur J Endocrinol, 160, pp.777~783 (2009)
28. Scialla JJ, "Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease", Clin J Am Soc Nephrol, 6, pp.2612~2619 (2011)
29. Raggi P, "Association of pulse wave velocity with vascular and valvular calcification in hemodialysis patients", Kidney Int, 71, pp.802~807 (2007)
30. Haydar AA, "Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients", Kidney Int, 65, pp.1790~1794 (2004)
31. Hjelmesaeth J, "Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients", J Am Soc Nephrol, 17, pp.1746~1754 (2006)
32. "Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease", Circulation, 109, pp.2175~2180 (2004)
33. Morena M, "Plasma osteoprotegerin is associated with mortality in hemodialysis patients", J Am Soc Nephrol, 17, pp.262~270 (2006)

관련 논문AI추천